z-logo
open-access-imgOpen Access
HER-2/neu overexpression in invasive ductal breast cancer: An association with other prognostic and predictive factors
Author(s) -
Tatjana Ivković-Kapicl,
Slavica Knežević-Ušaj,
Milana Panjković,
Dragana Djilas-Ivanovic,
Mileta Golubović
Publication year - 2007
Publication title -
archive of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.104
H-Index - 13
eISSN - 1450-9520
pISSN - 0354-7310
DOI - 10.2298/aoo0702015i
Subject(s) - breast cancer , immunohistochemistry , her2/neu , medicine , estrogen receptor , oncogene , lymph node , progesterone receptor , hormone receptor , receptor , cancer , pathology , oncology , cell cycle
Background: HER-2/neu is a proto-oncogene that is amplified/overexpressed in 15 to 30% of invasive breast cancers. The purpose of this study was to determine if any relationship exist between HER-2/neu protein overexpression and estrogen receptor (ER), progesterone receptor (PR), grade, size, and lymph node status in female breast cancer. Methods: A total of 100 cases of invasive ductal breast cancer were included in this study. The hormone receptors and HER-2/neu were studied immunohistochemically (IHC). Using the HER-2/neu DAKO scoring system, scores of 0, 1+ and 2+ were defined as negative and 3+ as positive. Results: HER-2/neu protein overexpression was seen in 20 (20%) of cases. HER-2/neu protein overexpression was present in 4 of 52 T1 lesions (8%), in 11 of 37 T2 lesions (30%), in 3 of 6 T3 lesions (50%), and in 2 of 5 T4 lesions (40%), (p<0.05). Protein overexpression was seen in 7 of 17 grade III tumors (41%), and 13 of 61 grade II tumors (21%). Overexpression was not detected in grade I tumors (p<0.01). Of the 20 Her-2/neu positive cases, ER- and PR-negative status was detected in 60% and 70%, respectively. Conclusion: Statistically significant correlation was found between HER-2/neu protein overexpression and large tumor size, high histological grade, and ER-, PR-negativity. There was no correlation with lymphonodal status

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here